An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab plus Ipilimumab, or Nivolumab plus platinum doublet chemotherapy versus platinum doublet chemotherapy in Subjects with Chemotherapy-Naïve Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)

drug protocol number
CA209-227
drug sponsor
Bristol-Myers Squibb
drug study
NIVOLUMAB/IPILIMUMAb
drug trial site
King Faisal Specialist Hospital and Research Center (Riyadh)
drug status
Terminated
drug phase